Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 23

1.

The Efficacy of Psychostimulants in Major Depressive Episodes: A Systematic Review and Meta-Analysis.

McIntyre RS, Lee Y, Zhou AJ, Rosenblat JD, Peters EM, Lam RW, Kennedy SH, Rong C, Jerrell JM.

J Clin Psychopharmacol. 2017 Aug;37(4):412-418. doi: 10.1097/JCP.0000000000000723.

PMID:
28590365
2.

Comparative efficacy and safety of attention-deficit/hyperactivity disorder pharmacotherapies, including guanfacine extended release: a mixed treatment comparison.

Joseph A, Ayyagari R, Xie M, Cai S, Xie J, Huss M, Sikirica V.

Eur Child Adolesc Psychiatry. 2017 Aug;26(8):875-897. doi: 10.1007/s00787-017-0962-6. Epub 2017 Mar 3. Review.

3.

A cost-effectiveness analysis of lisdexamfetamine dimesylate in the treatment of adults with attention-deficit/hyperactivity disorder in the UK.

Zimovetz EA, Joseph A, Ayyagari R, Mauskopf JA.

Eur J Health Econ. 2017 Jan 16. doi: 10.1007/s10198-016-0864-4. [Epub ahead of print]

PMID:
28093662
4.
5.

Binge-Eating Disorder in Adults: A Systematic Review and Meta-analysis.

Brownley KA, Berkman ND, Peat CM, Lohr KN, Cullen KE, Bann CM, Bulik CM.

Ann Intern Med. 2016 Sep 20;165(6):409-20. doi: 10.7326/M15-2455. Epub 2016 Jun 28. Review.

6.

Alternative pharmacological strategies for adult ADHD treatment: a systematic review.

Buoli M, Serati M, Cahn W.

Expert Rev Neurother. 2016;16(2):131-44. doi: 10.1586/14737175.2016.1135735. Epub 2016 Jan 14. Review.

PMID:
26693882
7.

Are there any potentially dangerous pharmacological effects of combining ADHD medication with alcohol and drugs of abuse? A systematic review of the literature.

Barkla XM, McArdle PA, Newbury-Birch D.

BMC Psychiatry. 2015 Oct 30;15:270. doi: 10.1186/s12888-015-0657-9. Review.

8.

Comparative efficacy, acceptability, and tolerability of lisdexamfetamine in child and adolescent ADHD: a meta-analysis of randomized, controlled trials.

Maneeton B, Maneeton N, Likhitsathian S, Suttajit S, Narkpongphun A, Srisurapanont M, Woottiluk P.

Drug Des Devel Ther. 2015 Apr 1;9:1927-36. doi: 10.2147/DDDT.S79071. eCollection 2015. Review.

9.
11.

Predicted effect size of lisdexamfetamine treatment of attention deficit/hyperactivity disorder (ADHD) in European adults: Estimates based on indirect analysis using a systematic review and meta-regression analysis.

Fridman M, Hodgkins PS, Kahle JS, Erder MH.

Eur Psychiatry. 2015 Jun;30(4):521-7. doi: 10.1016/j.eurpsy.2015.01.001. Epub 2015 Feb 25. Review.

PMID:
25725594
12.

Expert recommendation: contributions to clinical practice of the new prodrug lisdexamfetamine dimesylate (LDX) in the treatment of attention deficit hyperactivity disorder (ADHD).

Alda JA, Soutullo C, Ramos-Quiroga JA, Quintero J, Hervás A, Hernández-Otero I, Sans-Fitó A, Cardo-Jalón EC, Fernández-Jaén A, Fernández-Pérez M, Hidalgo-Vicario MI, Eddy-Ives LS, Sánchez J.

Actas Esp Psiquiatr. 2014 Dec;42 Suppl:1-16. Epub 2014 Dec 1.

13.

Exploratory meta-analysis on lisdexamfetamine versus placebo in adult ADHD.

Maneeton N, Maneeton B, Suttajit S, Reungyos J, Srisurapanont M, Martin SD.

Drug Des Devel Ther. 2014 Oct 3;8:1685-93. doi: 10.2147/DDDT.S68393. eCollection 2014. Review.

14.

Pharmacological interventions for adolescents and adults with ADHD: stimulant and nonstimulant medications and misuse of prescription stimulants.

Weyandt LL, Oster DR, Marraccini ME, Gudmundsdottir BG, Munro BA, Zavras BM, Kuhar B.

Psychol Res Behav Manag. 2014 Sep 9;7:223-49. doi: 10.2147/PRBM.S47013. eCollection 2014. Review.

15.

A systematic review of the safety of lisdexamfetamine dimesylate.

Coghill DR, Caballero B, Sorooshian S, Civil R.

CNS Drugs. 2014 Jun;28(6):497-511. doi: 10.1007/s40263-014-0166-2. Review.

16.

Systematic evidence synthesis of treatments for ADHD in children and adolescents: indirect treatment comparisons of lisdexamfetamine with methylphenidate and atomoxetine.

Roskell NS, Setyawan J, Zimovetz EA, Hodgkins P.

Curr Med Res Opin. 2014 Aug;30(8):1673-85. doi: 10.1185/03007995.2014.904772. Epub 2014 Apr 15. Review.

PMID:
24627974
17.

Practitioner review: current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents.

Cortese S, Holtmann M, Banaschewski T, Buitelaar J, Coghill D, Danckaerts M, Dittmann RW, Graham J, Taylor E, Sergeant J; European ADHD Guidelines Group.

J Child Psychol Psychiatry. 2013 Mar;54(3):227-46. doi: 10.1111/jcpp.12036. Epub 2013 Jan 7. Review.

PMID:
23294014
18.

Treating attention-deficit/hyperactivity disorder in adults: focus on once-daily medications.

Weisler RH, Childress AC.

Prim Care Companion CNS Disord. 2011;13(6). pii: PCC.11r01168. doi: 10.4088/PCC.11r01168.

19.

Understanding the effect size of lisdexamfetamine dimesylate for treating ADHD in children and adults.

Faraone SV.

J Atten Disord. 2012 Feb;16(2):128-37. doi: 10.1177/1087054710379738. Epub 2010 Sep 13.

PMID:
20837983
20.

Duration of effect of oral long-acting stimulant medications for ADHD throughout the day.

Brams M, Moon E, Pucci M, López FA.

Curr Med Res Opin. 2010 Aug;26(8):1809-25. doi: 10.1185/03007995.2010.488553. Review.

PMID:
20491612

Supplemental Content

Loading ...
Support Center